Maximizing germinal centers and somatic hypermutation to HIV Env immunogens
- Institution
- LA JOLLA INSTITUTE FOR IMMUNOLOGY, CA
- Principal investigator
- Shane P Crotty
- Funding
- $874K
- Duration
- 2016–2026
Moonbase score
Still being scored
Abstract
Abstract We propose that the features of germinal center biology important for developing high affinity B cells to a very difficult epitope, such as a tier 2 nAb epitope on HIV Env trimer, are very different than the well characterized features of GC biology for conventional antigens, such as haptens. We have demonstrated that slow delivery immunization changes fundamental aspects of the immune response, which can result in dramatic improvements in nAb responses (Cell 2019). Conventional immunization strategies will likely be insufficient for the development of a bnAb vaccine to HIV or other difficult pathogens due to the immunological hurdles posed, including B cell immunodominance and GC quantity and quality. We found that two independent methods of slow delivery immunization of RMs resulted in more robust Tfh cells and more GC B cells with Env-binding, tracked by longitudinal lymph node (LN) fine needle aspirates (FNA) 1. Improved GCs correlated with the development of > 20-fold higher titers of autologous tier 2 neutralizing Abs (nAbs). BCR sequencing and Ab mapping demonstrated targeting of immunodominant non-neutralizing (nnAb) epitopes by conventional bolus immunized animals, while slow delivery immunized animals targeted a more diverse set of epitopes, including multiple tier 2 nAb epitopes. We will continue these groundbreaking studies to use novel slow release technologies to probe the biology of germinal centers relevant to affinity maturation against a difficult HIV trimer immunogen in non-human primates (NHP, rhesus macaques).
Research team
- Shane P CrottyPI
- Darrell J IrvinePI
LOADING MOONBASE SCORE
Questions for LA JOLLA INSTITUTE FOR IMMUNOLOGY
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Univ of Massachusetts Med Sch WorcesterNot yet scored
Predictive drivers of new onset, relapse, and progression of human autoimmunity in skin
Manuel Garber · $1.2M · 2023–2028
- NIH · Icahn School of Medicine at Mount SinaiNot yet scored
Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery
Yizhou Dong · $730K · 2022–2027
- NIH · Massachusetts Institute of TechnologyNot yet scored
Immunotherapy via engineered therapeutic programs in tumors using RNA
Yizhou Dong · $640K · 2021–2026